Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AVMXYNASDAQ:BCRXNASDAQ:RXRXNASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVMXYAVITA MED LTD/S$7.89$7.89$1.06▼$8.58$651.87M1.28183,275 shsN/ABCRXBioCryst Pharmaceuticals$10.40-2.0%$9.29$5.92▼$11.31$2.18B1.113.04 million shs3.81 million shsRXRXRecursion Pharmaceuticals$5.17-4.3%$4.85$3.79▼$12.36$2.10B0.8414.85 million shs28.21 million shsVCELVericel$42.48-3.8%$41.34$37.39▼$63.00$2.14B1.33415,818 shs287,421 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVMXYAVITA MED LTD/S0.00%0.00%0.00%0.00%0.00%BCRXBioCryst Pharmaceuticals-3.63%-3.89%+2.61%+40.72%+63.73%RXRXRecursion Pharmaceuticals-0.92%+9.98%+16.38%-9.09%-37.06%VCELVericel-3.33%+2.34%+3.59%-2.67%+2.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVMXYAVITA MED LTD/SN/AN/AN/AN/AN/AN/AN/AN/ABCRXBioCryst Pharmaceuticals4.4238 of 5 stars4.41.00.04.23.41.70.6RXRXRecursion Pharmaceuticals1.9316 of 5 stars3.21.00.00.02.91.70.6VCELVericel2.6599 of 5 stars3.51.00.00.02.80.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVMXYAVITA MED LTD/S 0.00N/AN/AN/ABCRXBioCryst Pharmaceuticals 2.89Moderate Buy$16.5659.19% UpsideRXRXRecursion Pharmaceuticals 2.33Hold$7.6047.00% UpsideVCELVericel 3.00Buy$61.1443.93% UpsideCurrent Analyst Ratings BreakdownLatest AVMXY, BCRX, RXRX, and VCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.005/7/2025BCRXBioCryst PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $11.005/6/2025BCRXBioCryst PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$10.00 ➝ $13.005/6/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $17.005/6/2025BCRXBioCryst PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/6/2025RXRXRecursion PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $8.004/29/2025BCRXBioCryst PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$20.004/11/2025BCRXBioCryst PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $11.004/11/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$61.00 ➝ $51.004/10/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVMXYAVITA MED LTD/S$5.51M118.31N/AN/A$0.26 per share30.35BCRXBioCryst Pharmaceuticals$503.49M4.32N/AN/A($2.22) per share-4.68RXRXRecursion Pharmaceuticals$59.82M35.13N/AN/A$1.98 per share2.61VCELVericel$238.54M8.97$0.01 per share3,081.95$4.73 per share8.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVMXYAVITA MED LTD/S-$24.75M-$0.39N/A∞N/AN/AN/AN/AN/ABCRXBioCryst Pharmaceuticals-$226.54M-$0.26N/AN/AN/A-30.01%N/A-24.06%8/4/2025 (Estimated)RXRXRecursion Pharmaceuticals-$328.07M-$1.77N/AN/AN/A-579.52%-76.56%-55.68%8/6/2025 (Estimated)VCELVericel-$3.18M$0.03708.1296.55N/A1.56%1.48%0.96%7/30/2025 (Estimated)Latest AVMXY, BCRX, RXRX, and VCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025VCELVericel-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million5/5/2025Q1 2025RXRXRecursion Pharmaceuticals-$0.44-$0.50-$0.06-$0.50$18.12 million$14.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVMXYAVITA MED LTD/SN/AN/AN/AN/AN/ABCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVMXYAVITA MED LTD/SN/A5.505.33BCRXBioCryst PharmaceuticalsN/A2.782.73RXRXRecursion Pharmaceuticals0.044.354.35VCELVericelN/A4.614.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVMXYAVITA MED LTD/S0.01%BCRXBioCryst Pharmaceuticals85.88%RXRXRecursion Pharmaceuticals89.06%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipAVMXYAVITA MED LTD/SN/ABCRXBioCryst Pharmaceuticals4.80%RXRXRecursion Pharmaceuticals8.43%VCELVericel7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVMXYAVITA MED LTD/S5582.62 millionN/ANot OptionableBCRXBioCryst Pharmaceuticals530209.25 million197.19 millionOptionableRXRXRecursion Pharmaceuticals400406.50 million329.18 millionOptionableVCELVericel30050.34 million46.79 millionOptionableAVMXY, BCRX, RXRX, and VCEL HeadlinesRecent News About These CompaniesVericel Corporation: Moving From Sell To NeutralJune 12 at 11:03 AM | seekingalpha.comVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025June 11 at 6:06 PM | morningstar.comVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025June 10 at 8:30 AM | globenewswire.comGAMMA Investing LLC Acquires 127,028 Shares of Vericel Co. (NASDAQ:VCEL)June 10 at 3:32 AM | marketbeat.comVericel Co. (NASDAQ:VCEL) Receives $61.14 Consensus PT from AnalystsJune 10 at 2:15 AM | americanbankingnews.comCongress Asset Management Co. Purchases 22,579 Shares of Vericel Co. (NASDAQ:VCEL)June 7, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Given Average Recommendation of "Buy" by AnalystsJune 7, 2025 | marketbeat.comPortside Wealth Group LLC Buys New Position in Vericel Co. (NASDAQ:VCEL)June 6, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 16,466 Shares of Vericel Co. (NASDAQ:VCEL)June 3, 2025 | marketbeat.comWellington Management Group LLP Buys 701,064 Shares of Vericel Co. (NASDAQ:VCEL)May 30, 2025 | marketbeat.comVoloridge Investment Management LLC Acquires Shares of 27,345 Vericel Co. (NASDAQ:VCEL)May 30, 2025 | marketbeat.comVericel's (VCEL) Overweight Rating Reiterated at StephensMay 24, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Shares Purchased by Deutsche Bank AGMay 24, 2025 | marketbeat.com5VCEL : What Analysts Are Saying About Vericel StockMay 23, 2025 | benzinga.comVericel Co. (NASDAQ:VCEL) Stock Position Cut by BNP Paribas Financial MarketsMay 23, 2025 | marketbeat.comRafferty Asset Management LLC Lowers Stake in Vericel Co. (NASDAQ:VCEL)May 22, 2025 | marketbeat.comLazard Asset Management LLC Purchases 5,923 Shares of Vericel Co. (NASDAQ:VCEL)May 22, 2025 | marketbeat.comSoleus Capital Management L.P. Purchases Shares of 80,696 Vericel Co. (NASDAQ:VCEL)May 21, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Holdings Raised by D. E. Shaw & Co. Inc.May 20, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 124,122 Shares of Vericel Co. (NASDAQ:VCEL)May 19, 2025 | marketbeat.comVericel at BofA Securities Conference: Growth and Innovation in HealthcareMay 17, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVMXY, BCRX, RXRX, and VCEL Company DescriptionsAVITA MED LTD/S OTCMKTS:AVMXYAvita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.BioCryst Pharmaceuticals NASDAQ:BCRX$10.40 -0.21 (-1.98%) As of 04:00 PM EasternBioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Recursion Pharmaceuticals NASDAQ:RXRX$5.17 -0.23 (-4.26%) As of 04:00 PM EasternRecursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Vericel NASDAQ:VCEL$42.48 -1.70 (-3.85%) As of 04:00 PM EasternVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
